Sarepta Therapeutics (SRPT) says siRNA achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1
Context
Sarepta Therapeutics reported promising results for their siRNA treatment, indicating significant muscle concentrations without dose-limiting toxicity for FSHD1 and DM1. This outcome not only bodes well for their pipeline but may also lead to increased investor confidence and potential upward adjustments in stock price, impacting the broader biotech sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#SAREPTA THERAPEUTICS INC#SRPT.US#EU SESSION#US SESSION#US EQUITIES